Literature DB >> 26040715

Erratum: Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Sebastian Kreiter, Mathias Vormehr, Niels van de Roemer, Mustafa Diken, Martin Löwer, Jan Diekmann, Sebastian Boegel, Barbara Schrörs, Fulvia Vascotto, John C Castle, Arbel D Tadmor, Stephen P Schoenberger, Christoph Huber, Özlem Türeci, Ugur Sahin.   

Abstract

Entities:  

Year:  2015        PMID： 26040715     DOI： 10.1038/nature14567

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  1 in total

1.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Authors:  Sebastian Kreiter; Mathias Vormehr; Niels van de Roemer; Mustafa Diken; Martin Löwer; Jan Diekmann; Sebastian Boegel; Barbara Schrörs; Fulvia Vascotto; John C Castle; Arbel D Tadmor; Stephen P Schoenberger; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962
  1 in total
  5 in total

1.  Quantifying immune-based counterselection of somatic mutations.

Authors:  Fan Yang; Dae-Kyum Kim; Hidewaki Nakagawa; Shuto Hayashi; Seiya Imoto; Lincoln Stein; Frederick P Roth
Journal:  PLoS Genet       Date:  2019-07-25       Impact factor: 5.917

2.  The Cancer Epitope Database and Analysis Resource: A Blueprint for the Establishment of a New Bioinformatics Resource for Use by the Cancer Immunology Community.

Authors:  Zeynep Koşaloğlu-Yalçın; Nina Blazeska; Hannah Carter; Morten Nielsen; Ezra Cohen; Donald Kufe; Jose Conejo-Garcia; Paul Robbins; Stephen P Schoenberger; Bjoern Peters; Alessandro Sette
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 8.786

3.  Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer.

Authors:  Sanghoon Lee; Li Zhao; Christine Rojas; Nicholas W Bateman; Hui Yao; Olivia D Lara; Joseph Celestino; Margaret B Morgan; Tri V Nguyen; Kelly A Conrads; Kelly M Rangel; Robert L Dood; Richard A Hajek; Gloria L Fawcett; Randy A Chu; Katlin Wilson; Jeremy L Loffredo; Coralie Viollet; Amir A Jazaeri; Clifton L Dalgard; Xizeng Mao; Xingzhi Song; Ming Zhou; Brian L Hood; Nirad Banskota; Matthew D Wilkerson; Jerez Te; Anthony R Soltis; Kristin Roman; Andrew Dunn; David Cordover; Agda Karina Eterovic; Jinsong Liu; Jared K Burks; Keith A Baggerly; Nicole D Fleming; Karen H Lu; Shannon N Westin; Robert L Coleman; Gordon B Mills; Yovanni Casablanca; Jianhua Zhang; Thomas P Conrads; George L Maxwell; P Andrew Futreal; Anil K Sood
Journal:  Cell Rep       Date:  2020-04-14       Impact factor: 9.423

Review 4.  CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors.

Authors:  Anna C Filley; Mario Henriquez; Mahua Dey
Journal:  Front Oncol       Date:  2018-10-17       Impact factor: 6.244

5.  Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer.

Authors:  Caroline Laheurte; Magalie Dosset; Dewi Vernerey; Laura Boullerot; Béatrice Gaugler; Eléonore Gravelin; Vincent Kaulek; Marion Jacquin; Laurie Cuche; Guillaume Eberst; Pascale Jacoulet; Elizabeth Fabre; Françoise Le Pimpec-Barthes; Eric Tartour; Marcelo De Carvalho Bittencourt; Virginie Westeel; Olivier Adotévi
Journal:  Br J Cancer       Date:  2019-07-30       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.